Navigation Links
Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP

RADNOR, Pa., Jan. 2 /PRNewswire/ -- The following statement was issued today by the law firm of Schiffrin Barroway Topaz & Kessler, LLP:

Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Southern District of New York on behalf of all purchasers of the securities of Sanofi-Aventis (NYSE: SNY) ("Sanofi" or the "Company") from February 17, 2006 through June 13, 2007, inclusive (the "Class Period").

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Schiffrin Barroway Topaz & Kessler, LLP (Darren J. Check, Esq. or Richard A. Maniskas, Esq.) toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at

The Complaint charges Sanofi and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Sanofi is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. More specifically, the Complaint alleges that the Company failed to disclose material adverse data concerning Zimulti's tendency to cause a statistically significant increase in psychiatric problems, including suicidal thoughts and actions.

On June 13, 2007, an Advisory Panel to the Food and Drug Administration ("FDA") unanimously voted that Sanfi had not provided the panel with enough information on the safety of Zimulti (rimonabant), and unanimously recommended that the FDA reject Sanofi's Zimulti application. FDA scientists provided an analysis of 13 studies which showed that 26 percent of patients taking the recommended dose of Zimulti had psychiatric side effects, as compared to 14 percent of those patients who received a placebo. Additionally, studies showed that the drug also doubled cases of anxiety, depression, and other mood disorders when compared to placebo. Analysts had predicted that Zimulti would have been a multibillion-dollar product worldwide, assuming that it was approved in the US, which would have been the biggest market for the drug.

On this news, the Company's securities declined $1.31 per share, or 2.95 percent, to close on June 13, 2007 at $43.07 per share, on unusually heavy trading volume. The following day, the Company's securities declined an additional $1.74 per share, or over 4 percent, also on unusually heavy trading volume, for a two-day decline of $3.05 per share, or over 6.87 percent.

Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Schiffrin Barroway Topaz & Kessler which prosecutes class actions in both state and federal courts throughout the country. Schiffrin Barroway Topaz & Kessler is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.

For more information about Schiffrin Barroway Topaz & Kessler or to sign up to participate in this action online, please visit

If you are a member of the class described above, you may, not later than January 14, 2008, move the Court to serve as lead plaintiff of the class, if you so choose. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

CONTACT: Schiffrin Barroway Topaz & Kessler, LLP

Darren J. Check, Esq.

Richard A. Maniskas, Esq.

280 King of Prussia Road

Radnor, PA 19087

1-888-299-7706 (toll free) or 1-610-667-7706

Or by e-mail at

SOURCE Schiffrin Barroway Topaz & Kessler, LLP
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. CardioDynamics Provides 2007 Shareholder Meeting Update
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
5. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
6. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
8. Pharmos Issues Letter to Shareholders
9. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
10. Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
11. Coley Pharmaceutical Group Adopts Shareholder Rights Plan
Post Your Comments:
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
(Date:10/8/2015)... , Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, today ... partnering meetings taking place in the month of October: ... Partnering Forum RepliCel will be presenting at the ... on the Mesa to be held October 7-9 in ...
(Date:10/8/2015)... Claremont, CA (PRWEB) , ... October 08, 2015 ... ... by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and results ... abnormally viscous and sticky mucus accumulates in the lungs. This mucus is very ...
(Date:10/7/2015)... , Oct. 7, 2015  ChromaDex Corp. ... and nutritional ingredients that creates science-based solutions for ... nutrition, and pharmaceutical products, today announced that the ... CEO and Founder, is now available for on-demand ... -->   --> ...
Breaking Biology Technology:
... form of skin cancer, afflicts more than 50,000 people in ... rise. In a study published online in Genome ... ever before into the RNA world of the melanoma tumor ... the disease. The latest high-throughput DNA sequencing ...
... ... ... ... ...
... ... report on Fermenters market. The US market for fermenters is projected to reach $180 million ... biological drugs worldwide, and growing use of disposable or single-use fermenters. , ... San Jose, California (PRWEB) February 22, 2010 -- ...
Cached Biology Technology:
(Date:10/7/2015)... Sweden , October 8, 2015 ... the revenues for Fingerprint Cards (FPC) during third quarter 2015 ... revenue guidance of around 860 MSEK that was communicated 20 ... Considering a further strengthened delivery capacity and a continued growing ... quarter 2015 is estimated to be higher than during the ...
(Date:10/2/2015)... 02 2015 ... "Enforcing the Law Using Biometrics" report to ... announced the addition of the "Enforcing the ... --> Research and Markets ( ... "Enforcing the Law Using Biometrics" report to ...
(Date:9/29/2015)... -- News facts: , ... , Minimized design shrinks PC footprint , ... embedded Fujitsu PalmSecure authentication enable enterprises to realize benefits ... that good things come in small packages, with the ... desktop and mobile portfolio. Featuring workplace design that favors ...
Breaking Biology News(10 mins):
... that the clouded leopard found on the islands of Borneo ... secretive rainforest animal was originally thought to be the same ... , Genetic analysis conducted at the U.S. National Cancer ... species is comparable to the differences between other large cat ...
... Professor of Medicine and Pharmacology at the University of ... about 265 twin pairs over the past few years, ... "By studying many traits and genes, we have started ... Studying genetic variations in twins provides scientists with data ...
... in stem cell research may mean big things for cancer ... research team at the University of Kentucky published their findings ... The researchers genetically mapped a stem cell gene and its ... investigation all the way through to the identification of the ...
Cached Biology News:
... human XAB2 (amino terminus) XAB2 (XPA-binding ... interaction with XPA. Immunoprecipitation experiments have also ... with the transcription-coupled repair-specific proteins CSA and ... II. Microinjection experiments with XAB2 antibodies resulted ...
... maintenance, calibration, and validation (MCV) ... 96-well plate used for hands-free ... procedures using the Bio-Plex suspension ... is for use with Bio-Plex ...
Biology Products: